StocksMedium•9 November 2026•
1 min read
Eli Lilly's Foundayo Pill Shows Success in Sleep Apnea Clinical Trials
Key Facts
1Late-stage trials showed Eli Lilly's Foundayo pill significantly reduced obstructive sleep apnea events.
2Patients not using PAP therapy saw an average reduction of 21.1 apnea events per hour at 52 weeks.
3Eli Lilly plans to file for U.S. regulatory approval for the daily pill by the end of the year.
Late-stage trials showed Eli Lilly's Foundayo pill significantly reduced obstructive sleep apnea events. CNBC reported that patients not using PAP therapy saw an average reduction of 21.1 apnea events per hour at 52 weeks. Eli Lilly plans to file for U.S. regulatory approval for the daily pill by the end of the year.
Eli Lilly stock, traded under the ticker LLY, closed at $1354 on November 6, 2026, ahead of the announcement regarding these clinical results. The company is seeking to expand the clinical indications for its metabolic drug portfolio to include sleep-related disorders, strengthening its market position in obesity-related treatments.